Product Description
CuraSen Therapeutics is developing Clenbuterol as a treatment for Parkinson's disease. (Sourced from: https://www.curasen.com/curasen-therapeutics-to-present-phase-2-data-showing-rapid-onset-cognition-and-mood-benefit-with-cst-103-cst-107-clenbuterol-nadolol-in-parkinsons-disease-at-the-alzheimers-disease/)
Mechanisms of Action: ADRB2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Brazil | Bulgaria | Chile | Colombia | Czech | Dominican Republic | Ecuador | Germany | Hungary | India | Ireland | Italy | Korea | Malaysia | Mexico | Norway | Peru | Poland | Portugal | Russia | Taiwan | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: CuraSen Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Netherlands, New Zealand, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Cognitive Dysfunction|Dementia|Lewy Body Dementia|Lewy Body Disease|Movement Disorders|Parkinson's Disease|REM Sleep Behavior Disorder|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NL76746.068.21 | P2 |
Completed |
Type 2 Diabetes |
2024-03-01 |
|
| Clenbuterol study | P2 |
Active, not recruiting |
Type 2 Diabetes |
2023-10-01 |
|
| CLIN-011 | P2 |
Completed |
Lewy Body Dementia|Movement Disorders|Dementia|Parkinson's Disease|Lewy Body Disease|Cognitive Dysfunction|REM Sleep Behavior Disorder |
2022-07-04 |